Komori
JCR Pharmaceuticals (4552) · InitiativeAdvanced

Reducing Environmental Impact and Disclosures Aligned with the TCFD Recommendations

First written in FY2023. 3 of 4 entries say "Advanced", first in FY2024. Latest entry: FY2026.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024 – FY20262023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Setting GHG (CO2) emissions reduction targets and target achievement datesA theme 29 companies write about · 5 as a headwind · 16 as a tailwind

The whole theme swung hardest in 2024: 2 of 14 companies on the "Worse" side.

6 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 29 companies compared. The sentences above are computed from all 29.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Total GHG emissions increased approximately 9.4% year on year to 74,606tCO2 in fiscal 2025.」

    Total GHG emissions increased to 74,606tCO2. Scope 1 emissions were 2,764t, Scope 2 emissions were 7,886t and Scope 3 emissions were 63,955t. The Company also reported annual generation and sale of 54,080kWh of electricity from solar panels at its research facility.
  2. FY2025AdvancedAnnual report

    「At the new drug-substance plant, Kobe Science Park Center, completed in November 2022, the Company installed 588 solar panels, which supplied 7.1% of the plant's annual electricity consumption with renewable electricity that was effectively CO2-free.」

    The share of renewable energy supplied by the 588 solar panels at Kobe Science Park Center was 7.1%. Total GHG emissions increased 37.7% year on year to 68,185tCO2, due to an increase in Scope 3 emissions associated with the start of construction of the new formulation plant.
  3. FY2024AdvancedAnnual report

    「At the new drug-substance plant, Kobe Science Park Center, completed in November 2022, the Company installed 588 solar panels, which supplied 6.8% of the plant's annual electricity consumption.」

    As an environmental-impact reduction measure, the Company installed 588 solar panels at Kobe Science Park Center, supplying 6.8% of annual electricity consumption. GHG emissions were 49,516tCO2, down 56.2% year on year.
  4. FY2023First statedAnnual report

    「The Company regards the environmental impact of its business activities as a risk factor that could affect its business and society over the long term and is working to conduct environmentally responsible business activities, centered on the following 3 initiatives. Going forward, based on initiatives such as greenhouse gas (GHG) emissions-reduction targets set by each company and the Company's business plans, it will further advance initiatives toward achieving the Paris Agreement, including setting medium- to long-term GHG emissions-reduction targets.」

    The Company systematically disclosed, for the first time, energy consumption, water resources and disclosures aligned with the TCFD recommendations as environmental initiatives. GHG emissions totaled 88,048t, comprising Scope 1 of 3,315t, Scope 2 of 5,266t and Scope 3 of 79,466t. Detailed reduction targets were still being formulated.
Moved together

"Focused R&D and Faster, Lower-Risk Development Through Partnerships" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333333★123456
  1. ★This thread
  2. 1Focused R&D and Faster, Lower-Risk Development Through Partnerships3×
  3. 2Commercialization, Joint Research and Licensing of J-Brain Cargo®3×
  4. 3Expanding revenue from core products and strengthening the product portfolio3×
  5. 4Strengthening Business Development and Licensing Operations Leveraging Proprietary Technologies3×
  6. 5Expansion of Proprietary Biopharmaceutical Platform Technology3×
  7. 6Development of a Manufacturing and Cell Processing Center for Investigational Drugs3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Reducing Environmental Impact and Disclosures Aligned with the TCFD Recommendations | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori